肺移植治疗八例造血干细胞移植后闭塞性细支气管炎综合征的临床分析

OBJECTIVE: To investigate the efficacy and prognosis of lung transplantation (LT) for end-stage bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: The clinical data of eight cases with end-stage BOS after allo-HSCT who were treated by LT in our hospital were retrospectively analyzed. RESULTS: Eight patients with hematological malignancy underwent allo-HSCT, and the median age was 23 (12–40) years. The donors are parents or siblings. Severe BOS occurred in 8 patients after allo-HSCT, the median age for LT was 27.5 (13–47) years. The median interval between allo-HSCT and LT was 69 (21–132) months. The median follow-up time for 8 patients after LT was 15 (6–63) months, 7 patients survived, 1 patient died of pulmonary hemorrhage 15 months after LT treatment. Of the survivors, three had BOS again, and one of them received reduplicated lung transplantation. CONCLUSION: LT is an effective treatment for patients with severe BOS after HSCT.